Co-Pay Relief Program Fund Notices
Would you like to be notified when any new funds open, or when any of our current funds re-open? If so, please sign up using the “Get Notified” link below. As a member of our subscriber community you will receive important news about all of our disease funds, so join today!
This fund has been developed in response to patients who have contacted PAF for help with their medication expenses and could not find help. While this fund has been fully designed and we are ready to provide needed support to these patient communities, this fund is not yet able to accept applications for assistance as we are still working to secure charitable donations that will allow us to open it.
If you, or someone you know, would like to contribute to this fund, please visit our Donors page for more information on how to provide critical support for patients in need.Fund Type
Co-pay, Co-Insurance & DeductibleMaximum Award Level
$1,750 Per Year
- Household Income Requirements 400% or less of Federal Poverty Guideline (FPG) (adjusted for Cost of Living Index (COLI) and number in household)
- Insurance Requirements All Insurance Types
- Must reside and receive treatment in the United States.
Uveitis means inflammation of the uvea, or the middle layer of the eye wall. The uvea consists of three structures: the iris, the ciliary body, and the choroid. Inflammation occurring in any of these three structures is termed “uveitis.” Possible causes of uveitis are infection, injury, or an autoimmune or inflammatory disease. Many times a cause can’t be identified. The type of uveitis is classified by where inflammation occurs in the uvea: anterior uveitis is inflammation of the iris and ciliary body; intermediate uveitis is inflammation of the ciliary body; posterior uveitis is inflammation of the choroid and diffuse uveitis (also called panuveitis) is inflammation of all areas of the uvea. Uveitis occurs most frequently in people ages 20 to 60 and affects men and women equally. It can be acute or chronic. Uveitis can be serious and is estimated to be responsible for up to 10% of legal blindness in the U.S.